Here are eight key points on the company’s financial report:
1. Net sales were up 36 percent to $5.6 million.
2. There were 18 BoneScalpel units consigned in the United States during the quarter, which is a 50 percent increase. Now there are 324 units installed in the United States total.
3. Revenue for the BoneScalpel in the United States was up 93 percent to $1.7 million in the second quarter.
4. The company received royalty payments from Covidien of around $1 million during the quarter.
5. Misonix’s net income was $901,000. That’s $0.11 earnings per diluted share during the second quarter, nearly doubled from the same period last year.
6. For the six-month’s end, the total revenue was up 41 percent to $10.1 million.
7. The revenue increase was due to a 50 percent increase in BoneScalpel revenue to $5.2 million and a 39 percent increase in SonaStar revenue at $3.1 million. The SonicOne revenue also increased 43 percent to $1.4 million in revenue.
8. Net income for the first half of the year was $1.3 million, or $0.16 earning per diluted share. The same period last year experienced a $425,000 net loss.
More articles on orthopedic devices:
27 spine devices receives FDA 510(k) clearance in January
NuVasive COO sells 15k shares—5 things to know
5 things to know about Mazor’s new vice president of international l sales
